Literature DB >> 3782435

Binding of monoclonal antibody (4F2) to its cell surface antigen on dispersed adenomatous parathyroid cells raises cytosolic calcium and inhibits parathyroid hormone secretion.

J T Posillico, S Srikanta, G Eisenbarth, V Quaranta, S Kajiji, E M Brown.   

Abstract

In the course of characterizing monoclonal antibodies (MAbs) recognizing cell surface antigens on dispersed human parathyroid cells (dPTCs), we identified one MAb (4F2) that bound avidly to parathyroid cells and had marked effects on parathyroid function. The binding of MAb 4F2 to human adenomatous dPTCs resulted in a marked [53.8 +/- 7.9% (+/- SEM)] reduction in low calcium (Ca)-stimulated PTH secretion to levels equivalent to those in cell suppressed by high extracellular Ca (1.5 mM). Typically, these functional effects were optimal at antibody dilutions of 1:10(4) to 1:10(5). Cell viability was confirmed at the conclusion of each experiment by trypan blue exclusion (greater than 90-95%) and cell surface immunofluorescence. Parallel studies using the Ca-sensitive dye Quin-2 showed that inhibition of PTH secretion in 4F2-treated cells was associated with a concomitant increase in cytosolic Ca (Cai) of 188% in 0.5 mM Ca; these values also approached Cai levels in control cells incubated in high Ca. Mab controls, P3 X 63, which do not bind to dPTCs, and Mab LC7-2, which recognizes a different epitope of the same antigen as 4F2 on dPTCs, did not alter PTH secretion or Cai. Immunoprecipitation of 125I-labeled parathyroid cell extracts with MAb 4F2 demonstrated proteins with mol wt of approximately 145, 85, and 45 under nonreducing conditions and 85 and 45 kilodaltons after reduction with 5% mercaptoethanol. These studies suggest that 1) Mab-4F2 binding to its cell surface antigen inhibits PTH secretion by human adenomatous parathyroid cells in vitro; 2) the alterations in secretory function could be related to by an attendant increase in Cai; 3) the 4F2 antigen on dPTCs is a heterodimeric protein of (approximately) 85K and 45K; and 4) the 4F2 antigen may be an important component of the Ca-sensing and/or signal-transducing mechanism in this cell.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3782435     DOI: 10.1210/jcem-64-1-43

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Monoclonal antiparathyroid antibodies revealing defect expression of a calcium receptor mechanism in hyperparathyroidism.

Authors:  C Juhlin; G Akerström; L Klareskog; E Gylfe; H Johansson; R Larsson; S Ljunghall; P Nygren; J Rastad
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

2.  Activation of the calcium sensing receptor attenuates TRPV6-dependent intestinal calcium absorption.

Authors:  Justin J Lee; Xiong Liu; Debbie O'Neill; Megan R Beggs; Petra Weissgerber; Veit Flockerzi; Xing-Zhen Chen; Henrik Dimke; R Todd Alexander
Journal:  JCI Insight       Date:  2019-04-23

3.  Immunohistochemical study of nodular hyperplastic parathyroid glands in patients with secondary hyperparathyroidism.

Authors:  T Oka; T Yoshioka; G R Shrestha; T Koide; T Sonoda; S Hosokawa; K Onoe; M Sakurai
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

4.  Parathyroid crisis and acute viral hepatitis B infection.

Authors:  H E Mulcahy; F E Murray; R Freaney; J E Hegarty
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

5.  Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth.

Authors:  Robert C Rintoul; Robert C Buttery; Alison C Mackinnon; Weng Sie Wong; Deane Mosher; Christopher Haslett; Tariq Sethi
Journal:  Mol Biol Cell       Date:  2002-08       Impact factor: 4.138

6.  Beta1 integrins show specific association with CD98 protein in low density membranes.

Authors:  T V Kolesnikova; B A Mannion; F Berditchevski; M E Hemler
Journal:  BMC Biochem       Date:  2001-10-15       Impact factor: 4.059

7.  (18)F-FET-PET in Primary Hyperparathyroidism: A Pilot Study.

Authors:  Martin Krakauer; Andreas Kjaer; Finn N Bennedbæk
Journal:  Diagnostics (Basel)       Date:  2016-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.